新型（再）用途的老药：嘌呤能调节可能扑灭 COVID-19 的血栓炎症风暴。
New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm.
机构信息
Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Section of Vascular Thrombosis and Inflammation, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland, USA.
出版信息
JCI Insight. 2020 Jul 23;5(14):140971. doi: 10.1172/jci.insight.140971.
Abstract
Purinergic signaling is discussed as a potential therapeutic target to reduced COVID-19 severity.
摘要
嘌呤能信号转导被认为是降低 COVID-19 严重程度的潜在治疗靶点。
相似文献
1
New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm.新型（再）用途的老药：嘌呤能调节可能扑灭 COVID-19 的血栓炎症风暴。
JCI Insight. 2020 Jul 23;5(14):140971. doi: 10.1172/jci.insight.140971.
2
Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.直面争议：白细胞介素-6 与 COVID-19 细胞因子风暴综合征。
Eur Respir J. 2020 Oct 1;56(4). doi: 10.1183/13993003.03006-2020. Print 2020 Oct.
3
Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge.视神经脊髓炎谱系障碍患者在新冠疫情期间的免疫抑制：一项新挑战。
Mult Scler Relat Disord. 2020 Jun;41:102097. doi: 10.1016/j.msard.2020.102097. Epub 2020 Apr 5.
4
Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.熊去氧胆酸作为一种缓解和/或预防新冠病毒相关细胞因子风暴的候选治疗药物。
Med Hypotheses. 2020 Oct;143:109897. doi: 10.1016/j.mehy.2020.109897. Epub 2020 May 30.
5
COVID-19: Some clinical questions after the first 4 months.新冠病毒病（COVID-19）：最初4个月后的一些临床问题
Eur J Clin Invest. 2020 Jul;50(7):e13326. doi: 10.1111/eci.13326. Epub 2020 Jul 5.
6
Immune-Mediated Coagulopathy in COVID-19 Infection.新型冠状病毒肺炎感染中的免疫介导性凝血病
Semin Thromb Hemost. 2020 Oct;46(7):838-840. doi: 10.1055/s-0040-1714272. Epub 2020 Sep 2.
7
COVID-19 and Hypercoagulability.新型冠状病毒肺炎与高凝状态
Clin Adv Hematol Oncol. 2020 Jul;18(7):386-389.
8
versus SARS-CoV-2.与 SARS-CoV-2 相比。
ACS Chem Neurosci. 2020 Aug 19;11(16):2391-2392. doi: 10.1021/acschemneuro.0c00436. Epub 2020 Jul 27.
9
Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19.抗炎治疗可能会改善新冠肺炎的临床症状。
Ann Rheum Dis. 2020 Sep;79(9):1253-1254. doi: 10.1136/annrheumdis-2020-217562. Epub 2020 Apr 28.
10
Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.新型冠状病毒肺炎相关细胞因子风暴综合征的改善：与嵌合抗原受体T细胞细胞因子释放综合征的相似之处
Br J Haematol. 2020 Aug;190(3):e150-e154. doi: 10.1111/bjh.16961. Epub 2020 Jul 16.
引用本文的文献
1
The Purinergic Nature of Pseudoxanthoma Elasticum.弹性假黄瘤的嘌呤能性质
Biology (Basel). 2024 Jan 26;13(2):74. doi: 10.3390/biology13020074.
2
The adenosine hypothesis of schizophrenia into its third decade: From neurochemical imbalance to early life etiological risks.精神分裂症的腺苷假说进入第三个十年：从神经化学失衡到早期生活病因风险。
Front Cell Neurosci. 2023 Mar 14;17:1120532. doi: 10.3389/fncel.2023.1120532. eCollection 2023.
3
CD73: Friend or Foe in Lung Injury.CD73：肺损伤的友敌。
Int J Mol Sci. 2023 Mar 14;24(6):5545. doi: 10.3390/ijms24065545.
4
In vivo phenotypic validation of adenosine receptor-dependent activity of non-adenosine drugs.在体表型验证非腺苷类药物依赖于腺苷受体的活性。
Purinergic Signal. 2023 Sep;19(3):551-564. doi: 10.1007/s11302-023-09924-3. Epub 2023 Feb 13.
5
Venous Thromboembolism in Sepsis: From Bench to Bedside.脓毒症中的静脉血栓栓塞：从实验室到临床
Biomedicines. 2022 Jul 8;10(7):1651. doi: 10.3390/biomedicines10071651.
6
Extracellular ATP and Imbalance of CD4+ T Cell Compartment in Pediatric COVID-19.细胞外 ATP 与儿科 COVID-19 中 CD4+ T 细胞失衡。
Front Cell Infect Microbiol. 2022 May 18;12:893044. doi: 10.3389/fcimb.2022.893044. eCollection 2022.
7
Horizons of Heparin Therapy in COVID-19 and Pandemic-Related Diseases.COVID-19及大流行相关疾病中肝素治疗的前景
J Evol Biochem Physiol. 2022;58(2):523-534. doi: 10.1134/S002209302202020X. Epub 2022 May 16.
8
Persistent Lung Injury and Prothrombotic State in Long COVID.长新冠中的持续肺损伤和血栓前状态。
Front Immunol. 2022 Apr 7;13:862522. doi: 10.3389/fimmu.2022.862522. eCollection 2022.
9
Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic.与 COVID-19 大流行相关的 SARS-CoV-2 的免疫反应和潜在治疗策略。
Int J Biol Sci. 2022 Feb 14;18(5):1865-1877. doi: 10.7150/ijbs.66369. eCollection 2022.
10
Significance of Immune Status of SARS-CoV-2 Infected Patients in Determining the Efficacy of Therapeutic Interventions.新型冠状病毒感染患者的免疫状态在确定治疗干预疗效中的意义
J Pers Med. 2022 Feb 25;12(3):349. doi: 10.3390/jpm12030349.
本文引用的文献
1
Neutrophil extracellular traps and thrombosis in COVID-19.新冠病毒肺炎中的中性粒细胞胞外诱捕网与血栓形成
J Thromb Thrombolysis. 2021 Feb;51(2):446-453. doi: 10.1007/s11239-020-02324-z. Epub 2020 Nov 5.
2
Neutrophil calprotectin identifies severe pulmonary disease in COVID-19.中性粒细胞钙卫蛋白可识别 COVID-19 中的严重肺部疾病。
J Leukoc Biol. 2021 Jan;109(1):67-72. doi: 10.1002/JLB.3COVCRA0720-359R. Epub 2020 Sep 1.
3
COVID-19-associated coagulopathy: An exploration of mechanisms.COVID-19 相关凝血功能障碍：机制探索。
Vasc Med. 2020 Oct;25(5):471-478. doi: 10.1177/1358863X20932640. Epub 2020 Jun 19.
4
Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans.非裔美国人 COVID-19 患者的肺部和心脏病理学：来自新奥尔良的尸检系列。
Lancet Respir Med. 2020 Jul;8(7):681-686. doi: 10.1016/S2213-2600(20)30243-5. Epub 2020 May 27.
5
Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19.新冠病毒肺炎住院患者治疗剂量抗凝与院内生存的相关性
J Am Coll Cardiol. 2020 Jul 7;76(1):122-124. doi: 10.1016/j.jacc.2020.05.001. Epub 2020 May 6.
6
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.COVID-19 患者的病理性炎症：单核细胞和巨噬细胞的关键作用。
Nat Rev Immunol. 2020 Jun;20(6):355-362. doi: 10.1038/s41577-020-0331-4. Epub 2020 May 6.
7
Neutrophil extracellular traps in COVID-19.中性粒细胞胞外陷阱在 COVID-19 中的作用。
JCI Insight. 2020 Jun 4;5(11):138999. doi: 10.1172/jci.insight.138999.
8
Endothelial cell infection and endotheliitis in COVID-19.新型冠状病毒肺炎中的内皮细胞感染与内皮炎
Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21.
9
Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19.双嘧达莫对重症 COVID-19 患者的潜在治疗作用。
Acta Pharm Sin B. 2020 Jul;10(7):1205-1215. doi: 10.1016/j.apsb.2020.04.008. Epub 2020 Apr 20.
10
D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19.入院时 D-二聚体水平预测 COVID-19 患者住院死亡率。
J Thromb Haemost. 2020 Jun;18(6):1324-1329. doi: 10.1111/jth.14859.
Zotero 插件